Functional Immunopeptidomics by Characterizing Immunopeptides Against HLAs, TCRs, and Antibodies

The human body maintains a constant, silent vigil against cancer through a sophisticated surveillance system. At the heart of this defense are specialized proteins called human leukocyte antigens, or HLAs, which act as display windows on the surface of every cell. These windows hold up tiny fragments of the proteins inside the cell, allowing immune cells to scan them for signs of trouble. If a cell is healthy, the fragments look normal. If a cell is cancerous, it may display fragments that are mutated or chemically altered, signaling the immune system to attack. For years, scientists searching for new cancer treatments have focused almost entirely on finding these mutated fragments, hoping to design therapies that teach the immune system to recognize them. However, this approach hits a wall in many common cancers, such as kidney cancer, where the cells do not carry many mutations. In these cases, the immune system still manages to fight the disease, suggesting that the body is recognizing something else—perhaps fragments that are chemically modified in unique ways or proteins that are simply overproduced by the tumor. The challenge has been that the tools used to find these targets require large amounts of tissue and often miss the specific fragments that the immune system is actually engaging with, leaving researchers with a list of potential targets that may not be the real drivers of the immune response.

A team of researchers at Johns Hopkins University has developed a new way to look at this problem, one that works with tiny amounts of tissue and focuses on what the immune system is actually doing. Instead of just cataloging every fragment sitting on a cell's surface, their method separates the fragments that are being actively grabbed by immune receptors from those that are just passively sitting there. They tested this approach on thirty samples of kidney cancer tissue, including tumors and healthy tissue taken from the same patients. The process begins by grinding a mere ten milligrams of frozen tissue into a liquid. This liquid is then passed through a series of filters, each designed to catch a different type of immune interaction. First, the system captures fragments bound by antibodies, then those held by a specific type of immune receptor, followed by the general fragments displayed by the cell's main windows. Crucially, the researchers also took the immune receptors they had caught and mixed them back with the isolated fragments in a test tube to see which ones would stick together naturally. This allowed them to distinguish between fragments that are merely present and those that are functionally important.

The results revealed a landscape of targets far richer than previously seen. From these small samples, the team identified nearly thirty-nine thousand unique fragments displayed by the first type of immune window and nearly twenty-seven thousand unique fragments displayed by the second type. More importantly, when they looked at the fragments that were actively bound by immune receptors, they found that these were much more likely to be unique to the tumor and absent from healthy tissue. In fact, the method of catching these active interactions increased the purity of tumor-specific targets by up to five times compared to simply looking at all the fragments on the surface. The researchers also found that many of these important targets were not mutated at all. Instead, they were normal proteins that had been chemically altered, such as having a phosphate group attached, or they were proteins that the tumor was making in excessive amounts. Some of these targets appeared repeatedly across different patients, including proteins named NNMT, TMBIM6, RPL3, VIM, and ENPP3, suggesting they are reliable targets for therapy.

The study also uncovered a surprising difference in how the two types of immune windows are regulated. For the first type of window, the number of fragments displayed on the surface is directly linked to how much of the protein machinery is present in the cell; when the cell makes more of the machinery, it displays more fragments in a predictable, linear fashion. This is driven by a master switch in the cell's nucleus that turns on the entire production line. However, the second type of window behaves differently. The number of fragments it displays does not match the amount of protein machinery available. Even when the cell has plenty of the necessary components, the display of fragments can be low or inconsistent. The researchers found that this is because the second type of window relies on a complex, multi-step process of breaking down proteins inside the cell, and this process is often uneven or broken in cancer cells. Sometimes, the cell breaks down proteins too aggressively, destroying the very fragments needed for display, or it fails to process them correctly, leaving the windows empty despite the cell being full of the raw materials.

This work provides a clearer map of what the immune system is actually seeing in kidney cancer. By focusing on the fragments that are actively engaged by immune receptors and by working with very small tissue samples, the researchers have identified a set of high-priority targets that are both tumor-specific and functionally relevant. They found that the immune system is often responding to chemically modified versions of normal proteins and to proteins that are simply overproduced, rather than just mutated ones. The study also highlights that the rules governing how these targets are displayed are not the same for all parts of the immune system; one part follows a strict, predictable order, while the other is subject to a more chaotic and variable process. These findings suggest that future cancer therapies should look beyond simple mutations and consider these chemically modified and overproduced proteins as key targets. The new method offers a practical way to find these targets in patients with limited tissue samples, potentially accelerating the development of treatments that harness the body's own immune system to fight cancer more effectively.